Pharmacogenetic based precision therapy in childhood epilepsy: a case series

Prerna Choudhury; Aitha Vishaldeep; Kavita Srivastava

doi:10.18203/2349-3291.ijcp20263319

Authors

Prerna Choudhury Department of Pediatric Neurology, Bharati Hospital Bharati Vidyapeeth Campus, Dhankewadi, Katraj, Pune, Maharashtra, India
Aitha Vishaldeep Department of Pediatric Neurology, Bharati Hospital Bharati Vidyapeeth Campus, Dhankewadi, Katraj, Pune, Maharashtra, India
Kavita Srivastava Department of Pediatric Neurology, Bharati Hospital Bharati Vidyapeeth Campus, Dhankewadi, Katraj, Pune, Maharashtra, India

DOI:

https://doi.org/10.18203/2349-3291.ijcp20263319

Keywords:

Precision medicine, Genetic epilepsy, Epileptic encephalopathy, Pharmacogenomics

Abstract

Childhood epilepsy poses a significant burden for parents as well as healthcare systems. Drug refractory epilepsy (DRE) is predominantly caused by structural brain lesions or gene mutations affecting ion channels or neurotransmitter function affecting the brain networks. Precision medicine in childhood epilepsies has revolutionised the approach to children with DRE/DEE by tailoring medications based on clinical and molecular aspects. We present a case series of four paediatric patients with drug-resistant epilepsy who demonstrated inadequate seizure control with conventional antiseizure medications but showed significant clinical improvement following precision therapy guided by proposed mechanisms based on the gene defect.

Metrics

Metrics Loading ...

Author Biographies

Aitha Vishaldeep, Department of Pediatric Neurology, Bharati Hospital Bharati Vidyapeeth Campus, Dhankewadi, Katraj, Pune, Maharashtra, India

MD Paediatrics

IAP Fellow in Paediatric Neurology

Kavita Srivastava, Department of Pediatric Neurology, Bharati Hospital Bharati Vidyapeeth Campus, Dhankewadi, Katraj, Pune, Maharashtra, India

MD (Ped), FRCPCH, FPN (IAP)

Professor and Head of Unit

References

Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, et al. Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010;51(6):1069-77. DOI: https://doi.org/10.1111/j.1528-1167.2009.02397.x

Rastin C, Schenkel LC, Sadikovic B. Complexity in Genetic Epilepsies: A Comprehensive Review. Int J Mol Sci. 2023;24(19):14606. DOI: https://doi.org/10.3390/ijms241914606

Striano P, Minassian BA. From Genetic Testing to Precision Medicine in Epilepsy. Neurotherapeutics. 2020;17(2):609-15. DOI: https://doi.org/10.1007/s13311-020-00835-4

Menezes LFS, Sabiá Júnior EF, Tibery DV, Carneiro L dos A, Schwartz EF. Epilepsy-Related Voltage-Gated Sodium Channelopathies: A Review. Front Pharmacol. 2020;11:1276. DOI: https://doi.org/10.3389/fphar.2020.01276

Wolking S, May P, Mei D. Clinical spectrum of STX1B -related epileptic disorders. Neurology. 2019;92(11).

Dilena R, Striano P, Traverso M, Viri M, Cristofori G, Tadini L, et al. Dramatic effect of levetiracetam in early-onset epileptic encephalopathy due to STXBP1 mutation. Brain Dev. 2015;38(1):128-31. DOI: https://doi.org/10.1016/j.braindev.2015.07.002

Wang QH, Cao JJ, Wang YY, Zhang MN, Liu LY, Wang J, et al. Efficacy of levetiracetam in STXBP1 encephalopathy with different phenotypic and genetic spectra. Seizure. 2022;95:64-74. DOI: https://doi.org/10.1016/j.seizure.2021.12.006

Benke TA, Park K, Krey I, Camp CR, Song R, Ramsey AJ, et al. Clinical and therapeutic significance of genetic variation in the GRIN gene family encoding NMDARs. Neuropharmacology. 2021;199:108805. DOI: https://doi.org/10.1016/j.neuropharm.2021.108805

Cha JH, Kim JM, Yun HJ, Chin H, Kim HJ, Kim W, et al. Exploring gene-phenotype relationships in GRIN-related neurodevelopmental disorders. Npj Genomic Med. 2025;10(1):40. DOI: https://doi.org/10.1038/s41525-025-00499-z

Kuns B, Rosani A, Patel P, Varghese D. Memantine. In: StatPearls. StatPearls Publishing; 2026.

Karnstedt M, Perszyk RE, Myers SJ, McDaniels E, Somorai M, Borggraefe I, et al. Memantine treatment in individuals with GRIN gain‐of‐function variants is associated with improvements in behavior, development, and seizure frequency. Epilepsia. 2026;67(4):1961-74. DOI: https://doi.org/10.1002/epi.70090

Li J, Zhou Y, Su T, Xu S. Perampanel therapy for intractable GRIN2D-related developmental and epileptic encephalopathy: A case report and literature review. Brain Dev. 2023;45(4):237-43. DOI: https://doi.org/10.1016/j.braindev.2022.12.001

Madeo M, Stewart M, Sun Y, Sahir N, Wiethoff S, Chandrasekar I, et al. Loss-of-Function Mutations in FRRS1L Lead to an Epileptic-Dyskinetic Encephalopathy. Am J Hum Genet. 2016;98(6):1249-55. DOI: https://doi.org/10.1016/j.ajhg.2016.04.008

Ambrosino P, Ragona F, Mosca I, Vannicola C, Canafoglia L, Solazzi R, et al. A novel KCNC1 gain-of-function variant causing developmental and epileptic encephalopathy: “Precision medicine” approach with fluoxetine. Epilepsia. 2023;64(7):e148-55. DOI: https://doi.org/10.1111/epi.17656

Chen C, Wang L, Rong X, Wang W, Wang X. Effects of fluoxetine on protein expression of potassium ion channels in the brain of chronic mild stress rats. Acta Pharm Sin B. 2015;5(1):55-61. DOI: https://doi.org/10.1016/j.apsb.2014.12.004

Trivisano M, Mosca I, Salimbene L, De Dominicis A, Ambrosino P, Puzo D, et al. Fluoxetine Treatment in Epilepsy of Infancy with Migrating Focal Seizures Due to KCNT1 Variants: An Open Label Study. Ann Neurol. 2025;98(1):48-61. DOI: https://doi.org/10.1002/ana.27213

Li P, Butler A, Zhou Y, Magleby KL, Gurnett CA, Salkoff L. Case Report: Targeted treatment by fluoxetine/norfluoxetine of a KCNC2 variant causing developmental and epileptic encephalopathy. Front Pharmacol. 2025;15. DOI: https://doi.org/10.3389/fphar.2024.1528541